929617-35-6

Basic information

• Product Name: 5-bromo-1H-pyrazolo[3,4-c]pyridine
• Synonyms: 5-bromo-1H-pyrazolo[3,4-c]pyridine;4-c]pyridine;6-Aza-5-bromo-1H-indazole;1H-Pyrazolo[3,4-c]pyridine,5-broMo-;5-BroMo-1H-pyrazolo[3,4-c...
• CAS NO: 929617-35-6
• Molecular Formula: C₆H₄BrN₃
• Molecular Weight: 198.03
• EINECS: 200-589-5
• Product Categories: CHIRAL CHEMICALS;Heterocycle-Pyridine series
• Mol File: 929617-35-6.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 384 °C at 760 mmHg
• Flash Point: 186 °C
• Appearance: /
• Density: 1.894
• Vapor Pressure: 9.32E-06mmHg at 25°C
• Refractive Index: 1.745
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 9.68±0.40(Predicted)
• CAS DataBase Reference: 5-bromo-1H-pyrazolo[3,4-c]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-bromo-1H-pyrazolo[3,4-c]pyridine(929617-35-6)
• EPA Substance Registry System: 5-bromo-1H-pyrazolo[3,4-c]pyridine(929617-35-6)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 929617-35-6(Hazardous Substances Data)

Usage

General Description

5-Bromo-1H-pyrazolo[3,4-c]pyridine is a chemical compound with the molecular formula C7H4BrN3. It is a heterocyclic organic compound that contains a pyrazole ring fused to a pyridine ring, with a bromine atom attached to the pyrazole ring. 5-Bromo-1H-pyrazolo[3,4-c]pyridine is commonly used as a building block in the synthesis of pharmaceuticals and agrochemicals due to its reactivity and ability to participate in various organic reactions. 5-Bromo-1H-pyrazolo[3,4-c]pyridine has potential applications in the development of new drug candidates and crop protection products. Its unique structure makes it a valuable intermediate in the production of diverse functionalized molecules, making it an important chemical in the field of organic synthesis.

InChI:InChI=1/C6H4BrN3/c7-6-1-4-2-9-10-5(4)3-8-6/h1-3H,(H,9,10)

Upstream product

• 156118-16-0 6-bromo-4-methyl-pyridin-3-ylamine 
• 23056-47-5 2-bromo-4-methyl-5-nitropyridine 
• 543-87-3 isopentyl nitrate 

Downstream Products

• 929617-31-2 5-bromo-3-chloro-1H-pyrazolo[3,4-c]pyridine 
• 929617-41-4 tert-butyl 5-bromo-1H-pyrazolo[3,4-c]pyridine-1-carboxylate 
• 885223-61-0 1H-pyrazolo[3,4-c]pyridine-5-carbaldehyde 
• 1357947-08-0 5-bromo-3-iodo-1H-pyrazolo[3,4-c]pyridine 
• 633328-50-4 1H-pyrazolo[3,4-c]pyridine-5-carbonitrile 
• 1369509-72-7 5-bromo-3-iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-c]pyridine 

Relevant articles and documents

Discovery of (1 H-Pyrazolo[3,4- c]pyridin-5-yl)sulfonamide Analogues as Hepatitis B Virus Capsid Assembly Modulators by Conformation Constraint

Hepatitis B virus (HBV) capsid assembly modulators (CAMs) have been suggested to be effective anti-HBV agents in both preclinical and clinical studies. In addition to blocking HBV replication, CAMs could reduce the formation of covalently closed circular DNA (cccDNA), which accounts for the persistence of HBV infection. Here, we describe the discovery of (1H-indazole-5-yl)sulfonamides and (1H-pyrazolo[3,4-c]pyridin-5-yl)sulfonamides as new CAM chemotypes by constraining the conformation of the sulfamoylbenzamide derivatives. Lead optimization resulted in compound 56 with an EC50 value of 0.034 μM and good metabolic stability in mouse liver microsomes. To increase the solubility, the amino acid prodrug (65) and its citric acid salt (67) were prepared. Compound 67 dose dependently inhibited HBV replication in a hydrodynamic injection-based mouse model of HBV infection, while 56 did not show in vivo anti-HBV activity, likely owing to its suboptimal solubility. This class of compounds may serve as a starting point to develop novel anti-HBV drugs.

3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES AND THERAPEUTIC USES THEREOF

6-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 6-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-PYRROLO[2,3-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES AND THERAPEUTIC USES THEREOF

6-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 6-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.